ABVC Earnings & Financial Statements
ABVC BioPharma, Inc.
$1.02
+$0.04(+4.19%)
38
Overall
50
Value
30
Tech
34
Quality
Market Cap
$27.23M
Volume
55.90K
52W Range
$0.71 - $3.16
Target Price
$20.20
ABVC earnings and financial statements: ABVC BioPharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ABVC Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $509.6K | $152.4K | $969.8K | $355.8K |
| Cost of revenue | - | $763.00 | $302.0K | $286.4K | $5.1K |
| Operating income | -$7.15M | -$4.71M | -$6.77M | -$15.11M | -$11.71M |
| EBITDA | -$7.43M | -$4.34M | -$6.33M | -$15.20M | -$10.97M |
| Net income | -$7.91M | -$4.90M | -$7.79M | -$16.42M | -$12.84M |
| EPS (diluted) | $-0.39 | $-0.42 | $-2.43 | $-5.00 | $-5.10 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $21.06M | $7.54M | $7.78M | $9.58M | $13.70M |
| Total liabilities | $7.76M | $6.82M | $6.53M | $6.34M | $4.83M |
| Shareholders’ equity | $11.11M | $1.23M | $1.55M | $3.10M | $8.84M |
| Cash and equivalents | $681.5K | $248.4K | $60.2K | $85.3K | $5.83M |
| Long-term debt | $1.60M | $236.8K | $407.5K | $791.8K | $1.12M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$2.99M | -$1.81M | -$4.19M | -$7.40M | -$7.60M |
| Capital expenditure | -$5.8K | - | -$21.2K | -$119.7K | -$17.5K |
| Free cash flow | -$2.99M | -$1.81M | -$4.21M | -$7.52M | -$7.62M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABVC | $1.02 | +4.2% | 55.90K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |